Arkolith/Insider Trading/IKT/Form 4

Werner Milton H.

President and CEO, DirectorInhibikase Therapeutics, Inc. (IKT) · full profile →Form 4 · filed Jan 22, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
18
0 non-derivative · 18 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 21, 2025Grant(A)4K—$04K
Jan 21, 2025Disposed to issuer(D)4K—$00
Jan 21, 2025Grant(A)4K—$04K
Jan 21, 2025Disposed to issuer(D)4K—$00
Jan 21, 2025Grant(A)4K—$04K
Jan 21, 2025Disposed to issuer(D)4K—$00
Jan 21, 2025Grant(A)4K—$04K
Jan 21, 2025Disposed to issuer(D)17K—$00
Jan 21, 2025Grant(A)17K—$017K
Jan 21, 2025Disposed to issuer(D)21K—$00
Jan 21, 2025Grant(A)21K—$021K
Jan 21, 2025Disposed to issuer(D)4K—$00
Jan 21, 2025Grant(A)4K—$04K
Jan 21, 2025Grant(A)45K—$045K
Jan 21, 2025Disposed to issuer(D)45K—$00
Jan 21, 2025Disposed to issuer(D)4K—$00
Jan 21, 2025Disposed to issuer(D)35K—$00
Jan 21, 2025Grant(A)35K—$035K

Transaction Codes

A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-007741) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML